Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
130
Recruiting, any sponsor type, condition "ulcerative colitis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting130
- Completed486
130 trials
Showing 1 to 25, recently updated first.
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184996 · 980 participants (planned) · Start Oct 8, 2025 · Primary completion May 9, 2028
Drug: Duvakitug; Placebo · For: Ulcerative Colitis
Sites: Peoria, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 265 sites in all
- Modafinil For Fatigue in IBDRecruiting
Imperial College LondonAcademic, hospital or other
NCT07295834 · 70 participants (planned) · Start May 5, 2026 · Primary completion Dec 1, 2027
Drug: Modafinil; Placebo · For: Crohn Disease (CD); Ulcerative Colitis (UC); Fatigue
Sites: London, United Kingdom · 4 sites in all
National Cancer Institute (NCI)NIH
NCT03816345 · 300 participants (planned) · Start Jul 16, 2019 · Primary completion Mar 30, 2028
Drug: Cabozantinib; Fluoropyrimidine and 4 more · For: Autoimmune Disease; Crohn Disease; Dermatomyositis and 11 more
Sites: Birmingham, Alabama; Palo Alto, California; Sacramento, California · 52 sites in all
- A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisPivotal-lookingRecruiting
Spyre Therapeutics, Inc.Industry
NCT07012395 · 645 participants (planned) · Start May 27, 2025 · Primary completion Jun 2027
Drug: SPY001; SPY002 and 1 more · For: Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis and 1 more
Sites: Canoga Park, California; La Jolla, California; Lancaster, California · 279 sites in all
TakedaTakeda (TAK)
NCT06581328 · 200 participants (planned) · Start Mar 27, 2025 · Primary completion May 1, 2027
Drug: Vedolizumab IV; Vedolizumab SC · For: Ulcerative Colitis; Crohn's Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 101 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07665723 · 25 participants (planned) · Start Jun 29, 2026 · Primary completion Jul 31, 2027
Drug: Afimkibart; Caffeine and 4 more · For: Active Ulcerative Colitis
Sites: Chula Vista, California; Margate, Florida; Miami, Florida · 19 sites in all
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07758101 · 88 participants (planned) · Start Aug 21, 2026 · Primary completion Mar 31, 2028
Drug: SHR-7590; Placebo · For: Moderate-to-severe Inflammatory Bowel Disease
Sites: Guangzhou, China; Hangzhou, China
- A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)Pivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06405087 · 70 participants (planned) · Start Oct 27, 2025 · Primary completion Aug 12, 2030
Drug: Vedolizumab SC · For: Ulcerative Colitis; Crohn's Disease
Sites: Phoenix, Arizona; Loma Linda, California; Orange, California · 45 sites in all
- Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisRecruiting
Beijing VDJBio Co., LTD.Industry
NCT07932691 · 48 participants (planned) · Start Aug 9, 2024 · Primary completion Nov 30, 2028
Drug: Recombinant Human Interleukin-2 Fusion Protein with Human Serum Albumin (VDJ010); Placebo · For: Ulcerative Colitis (UC)
Sites: Hefei, China; Beijing, China; Xiamen, China · 6 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT06636656 · 80 participants (planned) · Start Dec 11, 2024 · Primary completion Jul 30, 2027
Drug: BI 3032950 intravenous (Part A); BI 3032950 subcutaneous (Part B) · For: Ulcerative Colitis
Sites: Scottsdale, Arizona; Colorado Springs, Colorado; Kissimmee, Florida · 42 sites in all
- A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Palisade BioIndustry
NCT07845487 · 204 participants (planned) · Start Aug 28, 2026 · Primary completion Oct 2027
Drug: PALI-2108; PALI-2108 and 1 more · For: Ulcerative Colitis (UC); Severe Ulcerative Colitis; Moderate Ulcerative Colitis
Sites: Sun City, Arizona; San Diego, California; Bristol, Connecticut · 114 sites in all
- Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)Pivotal-lookingRecruiting
Nanjing Immunophage Biotech Co., LtdIndustry
NCT07535489 · 144 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 1, 2028
Drug: IPG11406; Placebo · For: Moderately to Severely Active Ulcerative Colitis (UC)
Sites: Beijing, China
- A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07463183 · 100 participants (planned) · Start Mar 24, 2026 · Primary completion Oct 28, 2027
Drug: MK-8690 · For: Colitis Ulcerative; Ulcerative Colitis
Sites: Anaheim, California; Coronado, California; Colorado Springs, Colorado · 43 sites in all
Pontificia Universidad Catolica de ChileAcademic, hospital or other
NCT06758024 · 72 participants (planned) · Start Jan 24, 2025 · Primary completion Mar 2027
Drug: Infliximab; Infliximab · For: Inflammatory Bowel Disease (IBD); Crohn Disease (CD); Ulcerative Colitis (UC)
Sites: Santiago, Chile
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06651281 · 1,380 participants (planned) · Start Nov 25, 2024 · Primary completion Dec 17, 2037
Drug: Tulisokibart; Placebo to tulisokibart · For: Crohn Disease; Colitis, Ulcerative
Sites: Bristol, Connecticut; Ypsilanti, Michigan; Liberty, Missouri · 37 sites in all
- Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative ColitisPivotal-lookingRecruiting
Tanta UniversityAcademic, hospital or other
NCT07820046 · 44 participants (planned) · Start Oct 25, 2026 · Primary completion Jun 1, 2027
Drug: Nitazoxanide (NTZ) · For: Ulcerative Colitis (UC)
Sites: Tanta, Egypt · 2 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07747480 · 16 participants (planned) · Start Sep 3, 2026 · Primary completion Mar 5, 2028
Drug: Aletekitug · For: Colitis, Ulcerative
Sites: Oxford, United Kingdom
- A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07158242 · 100 participants (planned) · Start Apr 15, 2026 · Primary completion Mar 31, 2030
Drug: Afimkibart · For: Moderately to Severely Active Ulcerative Colitis
Sites: Aurora, Colorado; Hartford, Connecticut; Tampa, Florida · 29 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07483073 · 60 participants (planned) · Start May 4, 2026 · Primary completion Jun 2027
Drug: Mirikizumab - Intravenous (IV); Mirikizumab - Subcutaneous (SC) and 1 more · For: Colitis, Ulcerative; Crohn Disease
Sites: Scottsdale, Arizona; Los Angeles, California; Oxnard, California · 71 sites in all
- LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07415044 · 1,431 participants (planned) · Start Mar 26, 2026 · Primary completion Jun 2030
Drug: LY4268989; Placebo · For: Ulcerative Colitis (UC); Ulcerative Colitis, Active Moderate; Ulcerative Colitis, Active Severe
Sites: Phoenix, Arizona; Scottsdale, Arizona; Anaheim, California · 258 sites in all
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06937086 · 350 participants (planned) · Start Jun 26, 2025 · Primary completion Apr 2028
Drug: Mirikizumab; Mirikizumab and 2 more · For: Ulcerative Colitis; Obesity or Overweight
Sites: Dothan, Alabama; Anaheim, California; Beverly Hills, California · 186 sites in all
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07186101 · 252 participants (planned) · Start Nov 10, 2025 · Primary completion May 2027
Drug: LY4268989; Mirikizumab and 1 more · For: Ulcerative Colitis
Sites: Scottsdale, Arizona; Anaheim, California; Lancaster, California · 147 sites in all
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07577856 · 644 participants (planned) · Start May 23, 2026 · Primary completion Aug 11, 2028
Drug: JNJ-78934804; Guselkumab · For: Colitis, Ulcerative
Sites: Scottsdale, Arizona; Sun City, Arizona; Anaheim, California · 318 sites in all
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06663332 · 196 participants (planned) · Start Oct 29, 2024 · Primary completion Dec 12, 2031
Drug: Guselkumab · For: Crohns Disease; Colitis, Ulcerative; Arthritis, Psoriatic and 1 more
Sites: Atlanta, Georgia; Indianapolis, Indiana; Cincinnati, Ohio · 53 sites in all
Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04372108 · 1,536 participants (planned) · Start Jun 24, 2021 · Primary completion Aug 31, 2029
Drug: Ustekinumab; Other Biologic Therapies · For: Crohn Disease; Colitis, Ulcerative
Sites: Houston, Texas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.